🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05421455
Recruiting Not applicable

Surgery vs Biologics for Treating Stricturing CD--a RCT

NCT05421455 · tracked via the Priya Life Science China tracker
Sponsor
Zhu Weiming
Phase
Not applicable
Started
2022-06-09
Last updated
2026-07-09

Condition(s) studied

Crohn Disease

Investigational drug(s) / intervention(s)

Group AGroup B

Group A: treat participants with biologics

Group B: treat participants with surgery

Study summary

The management of stricturing Crohn's disease (CD) remains challenging. Although surgical resection may be the final way to solve it, the efficacy of biologics for symptomatic CD associated strictures was acceptable. In clinical practice, the chioce of treatment is particularly difficult. Therefore, a clinical trial of biologics versus surgery is needed to assess which one is prefered.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. with intestinal obstructive symptoms; 2. confirmed intestinal strictures; 3. traditional drugs failed to induce remission; 4. envidence of active bowel inflammation; 5. inappropriate for EBD; 6. acquirement of written informed consent of participant; Exclusion Criteria: 1. unsuccessful medical treatment of intestinal obstruction; 2. complete obstruction; 3. contraindication for biologics; 4. penetrating disease; 5. short smaal bowel; 6. suspicion of bowel tumor; 7. no confirmed strictures; 8. comitant severe disese of other system; 9. obstructive symptoms under over 2 targets of biologics; 10. successful treatment with traditional drugs; 11. participate other clinical research.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of General Surgery, Jinling hosptal,Medical School of Nanjing University Nanjing Jiangsu Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05421455 on ClinicalTrials.gov ↗ ← All trials in China